Preparation of Substituted 3-Aryl-5-trifluoromethyl-1,2,4-oxadiazoles
By using the reaction of trifluoroacetic acid alkyl esters with amamide oxime compounds in the presence of metal alkoxylates and inert solvents, the problems of low conversion rate and high cost in the preparation of 3-aryl-5-trifluoromethyl-1,2,4-diazole in the prior art have been solved, and efficient and safe industrial production has been achieved.
Patent Information
- Application Number
- CN202180013381.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-11-03
- Filing Date
- 2021-02-01
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2041-02-01
AI Technical Summary
Existing technologies for preparing 3-aryl-5-trifluoromethyl-1,2,4-diazole suffer from problems such as low conversion rate of amide oxime compounds, numerous byproducts, high operational risks, and high costs. In particular, it is difficult to achieve the goal of high yield and low byproduct amount in large-scale production.
The reaction of trifluoroacetic acid alkyl esters with amamide oxime compounds in the presence of metal alkoxylates was carried out at lower temperatures, using readily available, non-toxic, and inexpensive reactants, reducing excess acylating agent, employing inert solvents and conjugated Brønsted bases as bases, and optimizing reaction conditions to improve yield.
This study enables the preparation of 3-aryl-5-trifluoromethyl-1,2,4-diazole on an industrial scale with high yield and low by-product amount, reducing production costs and improving safety and ease of operation.
Smart Images

Figure CN115087645B_ABST
Abstract
Description
[0001] The present invention relates to a method for preparing a substituted 3-aryl-5-trifluoromethyl-1,2,4- The method for preparing oxadiazoles can be obtained by reacting an amide oxime compound of formula II with a haloacetic acid ester in the presence of a solvent and a base.
[0002]
[0003] Substituted 3-aryl-5-trifluoromethyl-1,2,4- Oxadiazoles are known for controlling phytopathogenic fungi, for example from WO 2015 / 185485 A1 and WO 2017 / 211649 A1.
[0004] Typically, 3-aryl-5-trifluoromethyl-1,2,4- The preparation of oxadiazoles involves the formation of oximes by reaction of an amide oxime compound, such as a compound of Formula II, with an activated derivative of trifluoroacetic acid (TFA). In the first reaction step, the hydroxyl group in the compound of formula II is acylated. Subsequently, the intermediate O-trifluoroacetamido oxime undergoes ring closure, followed by elimination of water to form Oxadiazole moiety.
[0005] Trifluoroacetic anhydride (TFAA) is commonly used as an acylating agent. In the above reaction, at least 2 equivalents of acylating agent are necessary to determine the complete conversion of compound II. Therefore, if TFAA is used, a total amount of at least 3 equivalents of TFA is formed per equivalent of compound II, which must be discarded. TFAA is quite expensive, and for the sake of atom efficiency, it is meaningful to reduce the excess TFA provided during or after the ring-closing reaction.
[0006] WO 2019 / 020451 A1 discloses the use of trifluoroacetyl halides instead of TFAA, which results in the formation of less TFA. However, the reaction still provides a significant amount of TFA and hydrogen halide, which may cause corrosion of the reaction equipment, and the hydrogen halide must eventually be separated from the reaction product. Trifluoroacetyl halides boil at low temperatures and are therefore not easy to operate, and since they are also highly toxic, they pose a risk to operators, particularly in large-scale devices.
[0007] The conversions described in the above references generate considerable amounts of TFA, which must be separated from the reaction products and disposed of. To improve atom efficiency, trifluoroacetic acid esters (TFAE) can be used in these processes, which are less reactive than TFAA or trifluoroacetyl halides toward the amide oximes of formula II. In theory, the use of esters instead of the corresponding acyl halide or anhydride requires only a small amount of excess acylating agent, if any.
[0008] Durden et al. describe a process in Journal of Organic Chemistry 1971, 36, 9, 1306-1307, in which (halogenated) vinyl acetate is used to react with benzamide oxime to obtain the corresponding Moderate yields (43%) were reported using vinyl trifluoroacetate.
[0009] WO 2017 / 22295 A1, WO 2017 / 222951 A1 and WO 2017 / 222952 A1 disclose the preparation of 3-aryl-5-trifluoromethyl-1,2,4- The reported yields were also modest.
[0010] In view of the above, an object of the present invention is to overcome these disadvantages and to provide an improved and more economical and production plant-friendly process which is capable of preparing 3-aryl-5-trifluoromethyl-1,2,4- Oxadiazole.
[0011] The present inventors have found that alkyl esters of trifluoroacetic acid can be reacted with amide oxime compounds of formula II in the presence of a metal alkoxide, which surprisingly provides higher yields of the desired Yield of oxadiazole.
[0012] The method of the present invention is environmentally friendly and more cost-effective than previously reported methods because it uses readily available, non-toxic and inexpensive reactants. The reaction can be carried out with a relatively low excess of acylating agent relative to the amide oxime raw material. In addition, rapid conversion of the raw materials is achieved at relatively low reaction temperatures.
[0013] Therefore, the present invention relates to a process for preparing a compound of formula I,
[0014]
[0015] in
[0016] A is phenyl or a 5- or 6-membered aromatic heterocycle; wherein the ring member atoms of the aromatic heterocycle include, in addition to carbon atoms, 1, 2, 3 or 4 heteroatoms selected from N, O and S as ring member atoms, provided that the heterocycle cannot contain 2 adjacent atoms selected from O and S; and wherein A is further unsubstituted or further substituted by n additional identical or different groups R A Replace;
[0017] n is 0, 1, 2, 3 or 4;
[0018] RA independently selected from halogen, cyano, C1-C6-alkyl, C1-C6-haloalkyl, C1-C6-alkoxy and C1-C6-haloalkoxy;
[0019] R is methyl, chloromethyl, hydroxymethyl, trichloromethyl, ethyl, isopropyl, OH, SH, cyano, halogen, CH2F, CHF2, 2,2,2-trifluoroethyl, cyclopropyl, -C(=O)H, -C(=NOR 2 )H, -C(=O)OH, -C(=O)OR 1 、-C(=W)NR 1 R 2 , -CR 3 R 4 NR 1 R 2 , -CR 3 R 4 OR 1 , -CR 3 (=NR 1 ),-CR 3 (=O)、-CR 3 R 4 C(=O)OH、-CR 3 R 4 C(=O)R 1 , -CR 3 R 4 C(=W)NR 1 R 2 , -OCR 3 R 4 C(=O)OH、-OCR 3 R 4 C(=O)R 1 , -OCR 3 R 4 C(=W)NR 1 R 2 , -CR 3 R 4 -N(R 2 )-C(=W)R 1 , -CR 3 R 4 S(=O)2R 1 or -CR 3 R 4 -N(R 2 )-S(=O)2R 1 ;in
[0020] W is O or S;
[0021] R 2is hydrogen, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-alkoxy, C3-C 11 -cycloalkyl, -C(=O)-C1-C6-alkyl, -C(=O)-C3-C 11 -cycloalkyl or -C(=O)-O-C1-C6-alkyl; and wherein R 2 Any aliphatic or cyclic radical in is unsubstituted or replaced by 1, 2, 3 or up to the maximum possible number of radicals selected from halogen, hydroxy, oxo, cyano, C1-C6-alkyl, C1-C6-alkoxy and C3-C 11 - substitution of cycloalkyl groups by the same or different groups;
[0022] R 1 It is C1-C6-alkyl, C1-C6-alkoxy, C3-C 11 -cycloalkyl, C3-C8-cycloalkenyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-alkoxyimino-C1-C4-alkyl, C2-C6-alkenyloxyimino-C1-C4-alkyl, C2-C6-alkynyloxyimino-C1-C4-alkyl, C1-C6-alkylamino, di-C1-C6-alkylamino, -C(=O)-C1-C6-alkyl, -C(=O)-O-C1-C6-alkyl, phenyl-C1-C4-alkyl, phenyl-C1-C4-alkenyl, phenyl-C1-C4-alkynyl, heteroaryl-C1-C4-alkyl, phenyl, naphthyl or a 3- to 10-membered saturated, partially unsaturated or aromatic monocyclic or bicyclic ring heterocycle, wherein the ring member atoms of the monocyclic or bicyclic heterocycle further include, in addition to carbon atoms, 1, 2, 3 or 4 heteroatoms selected from N, O and S as ring member atoms, provided that the heterocycle cannot contain 2 adjacent atoms selected from O and S; and wherein the heteroaryl in the group heteroaryl-C1-C4-alkyl is a 5- or 6-membered aromatic heterocycle, wherein the ring member atoms of the heterocyclic ring further include, in addition to carbon atoms, 1, 2, 3 or 4 heteroatoms selected from N, O and S as ring member atoms, provided that the heterocycle cannot contain 2 adjacent atoms selected from O and S; and wherein any of the above aliphatic or cyclic radicals is unsubstituted or replaced by 1, 2, 3 or up to the maximum possible number of identical or different radicals R 1a replace; or
[0023] R 1 and R 2, together with the nitrogen atom to which they are attached, form a saturated or partially unsaturated monocyclic or bicyclic 3- to 10-membered heterocyclic ring, wherein said heterocyclic ring apart from one nitrogen atom and one or more carbon atoms does not comprise further heteroatoms or comprises 1, 2 or 3 further heteroatoms independently selected from N, O and S as ring member atoms, provided that said heterocyclic ring cannot contain 2 adjacent atoms selected from O and S; and wherein said heterocyclic ring is unsubstituted or replaced by 1, 2, 3, 4 or up to the maximum possible number of identical or different radicals R 1a Replace;
[0024] R 1a is halogen, oxo, cyano, NO2, OH, SH, NH2, C1-C6-alkyl, C1-C6-haloalkyl, C1-C6-alkoxy, C1-C6-haloalkoxy, C1-C6-alkylthio, C1-C6-haloalkylthio, C3-C8-cycloalkyl, -NHSO2-C1-C4-alkyl, -C(=O)-C1-C4-alkyl, -C(=O)-O-C1-C4-alkyl, C1-C6-alkyl C1-C4-alkyl, -C(═O)-NH2, -C(═O)-NH(C1-C4-alkyl), C1-C4-alkylthio-C1-C4-alkyl, aminoC1-C4-alkyl, C1-C4-alkylamino-C1-C4-alkyl, di-C1-C4-alkylamino-C1-C4-alkyl, aminocarbonyl-C1-C4-alkyl or C1-C4-alkoxy-C1-C4-alkyl;
[0025] R 3 , R 4 are independently selected from hydrogen, halogen, cyano, C1-C4-alkyl, C1-C4-alkenyl, C1-C4-alkynyl, C1-C4-haloalkyl and C1-C4-alkoxy; or
[0026] R 3 and R 4 Together with the carbon atom to which they are bonded, they form a cyclopropyl group;
[0027] The method comprises reacting an amide oxime of formula II with a haloacetic acid ester of formula II.a in the presence of a solvent and a base,
[0028]
[0029] wherein the variables A and R are as defined above for compounds of formula I,
[0030]
[0031] Where R 5 is a C1-C6-alkyl group; and the method is characterized in that the base comprises a metal alkoxide of formula IV,
[0032] [C1-C6-alkyl-O] x M x+ IV
[0033] wherein the metal M is an alkali metal, wherein x is 1, or M is a divalent alkaline earth metal, wherein x is 2; and the solvent comprises an alkyl alcohol of formula III, or a mixture thereof,
[0034] C1-C6-Alkyl-OH III.
[0035] In one aspect of the invention, in the compounds of formula I and II the variable A is phenyl.
[0036] In one embodiment of the invention, the group R in the compounds of formula I and II A is halogen, C1-C6-alkyl, C1-C6-haloalkyl, C1-C6-alkoxy or C1-C6-haloalkoxy; in particular fluorine.
[0037] In one aspect, in the compounds of Formula I and II, n is 1 and R A For fluorine.
[0038] In a preferred embodiment, the variable n is 0 in the compounds of formula I and II.
[0039] In one aspect, the invention relates to a process as defined above, wherein the amide oxime is of formula II.b,
[0040]
[0041] wherein n is 0 or 1; and wherein R has the same meaning as defined or preferably defined herein for compounds of formula I; and wherein R A is selected from halogen, C1-C6-alkyl, C1-C6-haloalkyl, C1-C6-alkoxy and C1-C6-haloalkoxy; to obtain a Oxadiazole,
[0042]
[0043] The variables n, R A and R have the meanings as defined for compound II.b.
[0044] In another embodiment, in the compounds of formula Ib and II.b, n is 1 and R A For fluorine.
[0045] In a preferred embodiment, n is 0 in the compounds of the formula Ib and II.b.
[0046] In one embodiment, the variables in the compounds of formula I, II, Ib and II.b have the following meanings:
[0047] R A It is fluorine;
[0048] n is 0 or 1;
[0049] R is methyl, chloromethyl, hydroxymethyl, trichloromethyl, -C(=O)H, -C(=NOR 2 )H, -C(=O)OH, OH, SH, cyano, halogen, -C(=O)NR 1 R 2 、-CH2-N(R 2 )-C(=O)R 1 、-CH2-N(R 2 )-S(=O)2R 1 ,
[0050]
[0051] R 1 is methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, cyclopropyl, 2-methoxyiminoethyl, bicyclo[1.1.1]pent-1-yl or phenyl; and wherein phenyl is unsubstituted or substituted by 1, 2, 3 or up to the maximum possible number of identical or different radicals selected from fluorine, chlorine, cyano, methyl, ethyl, methoxy, trifluoromethyl, trifluoromethoxy, difluoromethyl, difluoromethoxy and cyclopropyl;
[0052] R 2 is hydrogen, methyl, ethyl, methoxy, ethoxy or cyclopropyl.
[0053] In a further embodiment, the variables in the compounds of formula I, II, Ib and II.b have the following meanings:
[0054] R A It is fluorine;
[0055] n is 0 or 1;
[0056] R is methyl, -C(=O)OH, -C(=O)NR 1 R 2 、-CH2-N(R 2 )-C(=O)R 1 、-CH2-N(R 2 )-S(=O)2R 1 ,
[0057]
[0058] R 1is C1-C6-alkyl, phenyl or cyclopropyl, wherein the phenyl ring is unsubstituted or substituted by 1, 2, 3 or 4 identical or different groups selected from halogen;
[0059] R 2 is hydrogen, methyl, ethyl, methoxy, ethoxy or cyclopropyl.
[0060] In yet another embodiment, the variables in the compounds of formula I, II, Ib and II.b have the following meanings:
[0061] R A It is fluorine;
[0062] n is 0 or 1;
[0063] R is -CH2-N(R 2 )-C(=O)R 1 、-CH2-N(R 2 )-S(=O)2R 1 ,
[0064]
[0065] R 1 is C1-C6-alkyl or cyclopropyl;
[0066] R 2 is hydrogen, methyl, methoxy, ethoxy or cyclopropyl.
[0067] In another embodiment, the variables in the compounds of formula I, II, Ib and II.b have the following meanings:
[0068] R A It is fluorine;
[0069] n is 0 or 1;
[0070] R is methyl, -C(=O)OH or -C(=O)NR 1 R 2 ;
[0071] R 1 is methyl or phenyl, wherein the phenyl ring is unsubstituted or substituted by 1, 2, 3 or 4 identical or different groups selected from halogen;
[0072] R 2 is hydrogen, methyl, ethyl, methoxy or ethoxy.
[0073] In yet another embodiment, the variables in the compounds of formula I, II, Ib and II.b have the following meanings:
[0074] n is 0;
[0075] R is -C(=O)NR1 R 2 ;
[0076] R 1 is methyl, 2-methoxyiminoethyl, bicyclo[1.1.1]pent-1-yl, 2-fluorophenyl, 4-fluorophenyl or 2,4-difluorophenyl; in particular methyl or 2-fluorophenyl;
[0077] R 2 It's hydrogen.
[0078] In one embodiment of the invention, the radical R in the haloacetic acid ester of formula II.a 5 is methyl, ethyl, n-propyl, isopropyl or n-butyl; preferably methyl or ethyl; especially ethyl.
[0079] In one embodiment, the reaction is carried out using 1 to 5 molar equivalents of the haloacetic acid ester II.a, based on the amount of the amidoxime II. Based on the amount of the amidoxime II, preference is given to using 1 to 3 molar equivalents, in particular 1.5 to 2.5 molar equivalents or 1.2 to 2 molar equivalents, even more preferably 1.5 to 2.2 molar equivalents or 1.2 to 1.6 molar equivalents.
[0080] Typically, the haloacetic acid ester of formula II.a is added to a solution of the amide oxime II and the base in a solvent. In one embodiment, the entire amount of the haloacetic acid ester II.a is added to the reaction mixture in portions or continuously over 2 to 8 hours.
[0081] In another embodiment, the base or a solution of the base in a solvent is added to a mixture of the amidoxime II and the haloacetic acid ester II.a, both of which are optionally dissolved or partially dissolved in the solvent. In one embodiment, the entire amount of the base is added to the reaction mixture in portions or continuously over 2-8 hours.
[0082] In a preferred embodiment, the metal M in the metal alkoxide of formula IV is sodium, potassium or magnesium; more preferably sodium or potassium; especially sodium.
[0083] In a more preferred embodiment, the metal alkoxide IV is sodium methoxide or sodium ethoxide or a mixture thereof.
[0084] In one embodiment of the invention, the alkoxylate base of formula IV is the corresponding conjugated Bronsted base of the solvent of formula III.
[0085] In a particularly preferred embodiment, the metal alkoxide IV is sodium methoxide and the solvent is methanol.
[0086] In another particularly preferred embodiment, the metal alkoxide IV is sodium ethoxide and the solvent is ethanol.
[0087] Typically, the base is added to the reaction mixture as a solution in an alkyl alcohol of formula III which is the corresponding conjugated Bronsted acid of the base.
[0088] The alkali is used in an amount of at least 80 mol %, or at least 100 mol %, or at least 150 mol %, based on the amount of the compound of formula II. In another aspect of the invention, the alkali is used in an amount of 80 to 1000 mol %, preferably 80 to 500 mol %, more preferably 90 to 200 mol %, particularly 90 to 140 mol %, based on the amount of the compound of formula II.
[0089] The process can be carried out in the presence of an inert solvent, also referred to herein as an auxiliary solvent. Suitable auxiliary solvents are, for example, aliphatic, alicyclic and aromatic hydrocarbons (pentane, hexane, petroleum ether, cyclohexane, methylcyclohexane, benzene, toluene, xylene), aliphatic halogenated hydrocarbons (methylene chloride, chloroform, dichloroethane and tetrachloroethane), nitriles (acetonitrile, propionitrile, benzonitrile), ethers (diethyl ether, dibutyl ether, tert-butyl methyl ether, ethylene glycol dimethyl ether, ethylene glycol diethyl ether, diethylene glycol dimethyl ether, 2-methyltetrahydrofuran, tetrahydrofuran, dioxane, diethylene glycol monomethyl ether or monoethyl ether), N-substituted lactams (N-methylpyrrolidone), formamides (N,N-dimethylformamide, N,N-dimethylacetamide), acyclic ureas (dimethylimidazolinium), nitriles (such as acetonitrile or propionitrile) and sulfoxides and sulfones (dimethyl sulfoxide, dimethyl sulfoxide, tetramethylene sulfoxide, sulfolane).
[0090] Preferred auxiliary solvents are benzene, toluene, xylene, cyclohexane, n-hexane, n-heptane, tetrahydrofuran, dioxane, N,N-dimethylformamide, N-methylpyrrolidine or dimethyl sulfoxide.
[0091] According to the present invention, the solvent comprises an alkyl alcohol of formula III, or a mixture thereof,
[0092] C1-C6-Alkyl-OH III.
[0093] Specifically, in one embodiment of the present invention, the process is carried out in the presence of a solvent comprising methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, sec-butanol or tert-butanol or a mixture thereof.
[0094] In a particularly preferred embodiment, the process is carried out in the presence of a solvent comprising methanol or ethanol or a mixture thereof.
[0095] In one aspect, the process is carried out in the presence of a solvent comprising an alkyl alcohol of formula III as defined or preferably defined above, and the solvent contains at least 1% by volume of an alkyl alcohol of formula III or a mixture thereof, based on the total amount of solvent, i.e. any other solvent; and such other solvent comprises an auxiliary solvent or a halogenated acetic acid ester of formula II.a or a mixture thereof.
[0096] In another aspect, the process is carried out in the presence of a solvent comprising an alkyl alcohol of formula III as defined or preferably defined above, and the solvent contains at least 5% by volume of an alkyl alcohol of formula III or a mixture thereof, based on the total amount of solvent, i.e. any other solvent; and such other solvent comprises an auxiliary solvent or a halogenated acetic acid ester of formula II.a or a mixture thereof.
[0097] In one aspect, the process is carried out in the presence of an alkyl alcohol of formula III or a mixture thereof and in the absence of any other co-solvent.
[0098] The reaction temperature of the above method is preferably in the range of 0°C to 60°C; preferably in the range of 10°C to 50°C or in the range of 20°C to 50°C.
[0099] The reaction is usually carried out within 10 minutes to 20 hours, or within 60 minutes to 14 hours, preferably within 1 to 10 hours, or within 2 to 10 hours, more preferably within 2 to 8 hours.
[0100] In a particularly preferred embodiment, the process is carried out in the presence of a solvent comprising methanol or ethanol or a mixture thereof; and wherein the metal alkoxide IV is sodium methoxide or sodium ethoxide or a mixture thereof; and wherein the reaction temperature of the above process is in the range of 0°C to 60°C.
[0101] In another particularly preferred embodiment, the process is carried out in the presence of a solvent comprising an alkyl alcohol, the alkyl alcohol comprising methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, sec-butanol or tert-butanol or a mixture thereof; and wherein the alkoxylate base of formula IV corresponds to the conjugated Bronsted base of the alkyl alcohol; and wherein the reaction temperature of the above process is in the range of 0°C to 60°C; and the solvent contains at least 1% by volume of the alkyl alcohol or a mixture thereof, based on the total amount of solvent, i.e., any other solvent; and such other solvents include auxiliary solvents or halogenated acetic acid esters of formula II.a or mixtures thereof.
[0102] In another particularly preferred embodiment, the process is carried out in the presence of a solvent comprising methanol or ethanol or a mixture thereof; and wherein the metal alkoxide IV is sodium methoxide or sodium ethoxide or a mixture thereof; and wherein the reaction temperature of the above process is in the range of 0°C to 60°C; and the solvent contains at least 1% by volume of an alkyl alcohol of formula III or a mixture thereof, based on the total amount of solvent, i.e., any other solvent; and such other solvent comprises an auxiliary solvent or a halogenated acetate of formula II.a or a mixture thereof; or even more preferably, the alkoxide base of formula IV corresponds to a conjugated Bronsted base of the solvent of formula III.
[0103] In another particularly preferred embodiment, the process is carried out in the presence of a solvent comprising methanol or ethanol or a mixture thereof; and wherein the metal alkoxide IV is sodium methoxide or sodium ethoxide or a mixture thereof; and wherein the reaction temperature of the above process is in the range of 10°C to 50°C; and the solvent contains at least 5% by volume of an alkyl alcohol of formula III or a mixture thereof, based on the total amount of solvent, i.e., any other solvent; and such other solvent comprises an auxiliary solvent or a halogenated acetate of formula II.a or a mixture thereof; or even more preferably, the alkoxide base of formula IV corresponds to a conjugated Bronsted base of the solvent of formula III.
[0104] The process of the invention is usually carried out at atmospheric pressure. In another embodiment, the process is carried out in a closed reactor to avoid loss of low-boiling compounds III by vapor pressure or nitrogen purging. In this case, a small amount of overpressure is generated by heating or metering one of the starting materials.
[0105] In a preferred embodiment of the present invention (embodiment E.1), the metal M in the metal alkoxide IV is sodium, potassium or magnesium.
[0106] Embodiment E.2: Based on embodiment E.1, wherein the group R in the halogenated acetic acid ester of formula II.a 5 It is methyl or ethyl.
[0107] Embodiment E.3: Based on embodiment E.2, wherein the amount of the haloacetic acid ester of formula II.a is between 1.5 and 2.5 equivalents based on the amount of amide oxime II.
[0108] Embodiment E.4: Based on embodiment E.3, wherein the metal alkoxide IV is sodium methoxide or sodium ethoxide or a mixture thereof.
[0109] Embodiment E.5: Based on Embodiment E.4, wherein the solvent comprises an alkyl alcohol of Formula III or a mixture thereof.
[0110] Embodiment E.6: Based on embodiment E.5, wherein the solvent comprises methanol or ethanol or a mixture thereof.
[0111] Embodiment E.7: Based on Embodiment E.6, wherein the alkoxylate base of Formula IV corresponds to a conjugated Bronsted base of a solvent of Formula III.
[0112] Embodiment E.8: Based on embodiment E.7, wherein the method is carried out in the presence of a solvent comprising an alkyl alcohol of formula III as defined or preferably defined herein, and the solvent contains at least 1 volume % of an alkyl alcohol of formula III or a mixture thereof, based on the total amount of solvent, i.e., any other solvent; and such other solvent includes an auxiliary solvent or a halogenated acetate of formula II.a or a mixture thereof.
[0113] Embodiment E.9: Based on embodiment E.8, wherein the method is carried out at a temperature of 0°C to 60°C.
[0114] Embodiment E.10: Based on embodiment E.4, wherein the method is carried out at a temperature of 0°C to 60°C.
[0115] Embodiment E.11: Based on Embodiment E.9, the variables in the compounds of Formula I, II, Ib and II.b have the following meanings:
[0116] R A It is fluorine;
[0117] n is 0 or 1;
[0118] R is methyl, chloromethyl, hydroxymethyl, trichloromethyl, -C(=O)H, -C(=NOR 2 )H, -C(=O)OH, OH, SH, cyano, halogen, -C(=O)NR 1 R 2 、-CH2-N(R 2 )-C(=O)R 1 、-CH2-N(R 2 )-S(=O)2R 1 ,
[0119]
[0120] R 1 is methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, cyclopropyl, 2-methoxyiminoethyl, bicyclo[1.1.1]pent-1-yl or phenyl; and wherein phenyl is unsubstituted or substituted by 1, 2, 3 or up to the maximum possible number of identical or different radicals selected from fluorine, chlorine, cyano, methyl, ethyl, methoxy, trifluoromethyl, trifluoromethoxy, difluoromethyl, difluoromethoxy and cyclopropyl;
[0121] R 2 is hydrogen, methyl, ethyl, methoxy, ethoxy or cyclopropyl.
[0122] Embodiment E.12: Based on Embodiment E.9, the variables in the compounds of Formula I, II, Ib and II.b have the following meanings:
[0123] R A It is fluorine;
[0124] n is 0 or 1;
[0125] R is methyl, -C(=O)OH or -C(=O)NR 1 R 2 ;
[0126] R 1 is methyl or phenyl, wherein the phenyl ring is unsubstituted or substituted by 1, 2, 3 or 4 identical or different groups selected from halogen;
[0127] R 2 is hydrogen, methyl, ethyl, methoxy or ethoxy.
[0128] Embodiment E.13: Based on Embodiment E.10, the variables in the compounds of Formula I, II, Ib and II.b have the following meanings:
[0129] R A It is fluorine;
[0130] n is 0 or 1;
[0131] R is methyl, chloromethyl, hydroxymethyl, trichloromethyl, -C(=O)H, -C(=NOR 2 )H, -C(=O)OH, OH, SH, cyano, halogen, -C(=O)NR 1 R 2 、-CH2-N(R 2 )-C(=O)R 1 、-CH2-N(R 2 )-S(=O)2R 1 ,
[0132]
[0133] R 1 is methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, cyclopropyl, 2-methoxyiminoethyl, bicyclo[1.1.1]pent-1-yl or phenyl; and wherein phenyl is unsubstituted or substituted by 1, 2, 3 or up to the maximum possible number of identical or different radicals selected from fluorine, chlorine, cyano, methyl, ethyl, methoxy, trifluoromethyl, trifluoromethoxy, difluoromethyl, difluoromethoxy and cyclopropyl;
[0134] R 2is hydrogen, methyl, ethyl, cyclopropyl, methoxy or ethoxy.
[0135] Embodiment E.14: Based on Embodiment E.10, the variables in the compounds of Formula I, II, Ib and II.b have the following meanings:
[0136] R A It is fluorine;
[0137] n is 0 or 1;
[0138] R is methyl, -C(=O)OH or -C(=O)NR 1 R 2 ;
[0139] R 1 is methyl or phenyl, wherein the phenyl ring is unsubstituted or substituted by 1, 2, 3 or 4 identical or different groups selected from halogen;
[0140] R 2 is hydrogen, methyl, ethyl, methoxy or ethoxy.
[0141] In a further embodiment of the invention, compounds of the formula I or Ib in which R is methyl are converted into valuable chemical products or intermediates.
[0142] Accordingly, in one embodiment, the compound of formula Ib wherein n is 0 and R is methyl can be further chlorinated to obtain the compound of formula Ic
[0143]
[0144] Chlorination of the methyl group R of the compound of formula I or Ib can be achieved as described in WO 2019 / 020451 A1 and the references cited therein.
[0145] In a further embodiment, the compound of formula Ic is hydrolyzed to obtain a compound of formula III.a
[0146]
[0147] In one embodiment, as described in WO 2019 / 020451 A1 and the references cited therein, this conversion is carried out in the presence of a catalytic amount of a Lewis acid and water to obtain a compound of formula III.a. Preferably, the Lewis acid is a metal salt, such as aluminum (III) chloride or iron (III) chloride, in particular iron (III) chloride.
[0148] In another embodiment, the compound of formula Ib wherein n is 0 and R is -C(=O)OH is chlorinated to obtain a compound of formula III.a
[0149]
[0150] These transformations are described in WO 2019 / 020451 A1 and WO 2017 / 211649 A1 and the references cited therein.
[0151] In one embodiment, a compound of formula III.a is reacted with an amine of formula IV,
[0152] R 1 -NH-R 2 IV
[0153] in
[0154] R 1 It is C1-C6-alkyl, C1-C6-alkoxy, C3-C 11 -cycloalkyl, C3-C8-cycloalkenyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-alkoxyimino-C1-C4-alkyl, C2-C6-alkenyloxyimino-C1-C4-alkyl, C2-C6-alkynyloxyimino-C1-C4-alkyl, C1-C6-alkylamino, di-C1-C6-alkylamino, -C(=O)-C1-C6-alkyl, -C(=O)-O-C1-C6-alkyl, phenyl-C1-C4-alkyl, phenyl-C1-C4-alkenyl, phenyl-C1-C4-alkynyl, heteroaryl-C1-C4-alkyl, phenyl, naphthyl or a 3- to 10-membered saturated, partially unsaturated or aromatic monocyclic or bicyclic ring heterocycle, wherein the ring member atoms of the monocyclic or bicyclic heterocycle further include, in addition to carbon atoms, 1, 2, 3 or 4 heteroatoms selected from N, O and S as ring member atoms, provided that the heterocycle cannot contain 2 adjacent atoms selected from O and S; and wherein the heteroaryl in the group heteroaryl-C1-C4-alkyl is a 5- or 6-membered aromatic heterocycle, wherein the ring member atoms of the heterocyclic ring further include, in addition to carbon atoms, 1, 2, 3 or 4 heteroatoms selected from N, O and S as ring member atoms, provided that the heterocycle cannot contain 2 adjacent atoms selected from O and S; and wherein any of the above aliphatic or cyclic radicals is unsubstituted or replaced by 1, 2, 3 or up to the maximum possible number of identical or different radicals R 1a replace; or
[0155] R 1 and R 2, together with the nitrogen atom to which they are attached, form a saturated or partially unsaturated monocyclic or bicyclic 3- to 10-membered heterocyclic ring, wherein said heterocyclic ring apart from one nitrogen atom and one or more carbon atoms does not comprise further heteroatoms or comprises 1, 2 or 3 further heteroatoms independently selected from N, O and S as ring member atoms, provided that said heterocyclic ring cannot contain 2 adjacent atoms selected from O and S; and wherein said heterocyclic ring is unsubstituted or replaced by 1, 2, 3, 4 or up to the maximum possible number of identical or different radicals R 1a Replace;
[0156] R 1a is halogen, oxo, cyano, NO2, OH, SH, NH2, C1-C6-alkyl, C1-C6-haloalkyl, C1-C6-alkoxy, C1-C6-haloalkoxy, C1-C6-alkylthio, C1-C6-haloalkylthio, C3-C8-cycloalkyl, -NHSO2-C1-C4-alkyl, (C=O)-C1-C6-alkyl, C(=O)-O-C1-C6-alkyl, C1-C6-alkoxy C1-C4-alkyl, alkylsulfonyl, hydroxyC1-C4-alkyl, C(═O)—NH2, C(═O)—NH(C1-C4-alkyl), C1-C4-alkylthio-C1-C4-alkyl, aminoC1-C4-alkyl, C1-C4-alkylamino-C1-C4-alkyl, di-C1-C4-alkylamino-C1-C4-alkyl, aminocarbonyl-C1-C4-alkyl or C1-C4-alkoxy-C1-C4-alkyl;
[0157] R 2 is hydrogen, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-alkoxy, C3-C 11 -cycloalkyl, -C(=O)H, -C(=O)-C1-C6-alkyl, -C(=O)-C3-C 11 -cycloalkyl or -C(=O)-O-C1-C6-alkyl; and wherein R 2 Any aliphatic or cyclic radical in is unsubstituted or replaced by 1, 2, 3 or up to the maximum possible number of radicals selected from halogen, hydroxy, oxo, cyano, C1-C6-alkyl, C1-C6-alkoxy and C3-C 11 - substitution of cycloalkyl groups by the same or different groups;
[0158] To obtain a compound of formula V
[0159]
[0160] These transformations are also described in WO 2019 / 020451 A1 and WO 2017 / 211652 A1 and the references cited therein.
[0161] In another embodiment, the compound of formula V is used to obtain the compound of formula VI as described in WO 2019 / 020451 A1 and WO 2017 / 211649 A1 and the references cited therein
[0162]
[0163] In a preferred embodiment, the variable R in the compounds of formula I, Ib, II.b, IV, V and VI 1 and R 2 Has the following meanings:
[0164] R 1 is methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, cyclopropyl, 2-methoxyiminoethyl, bicyclo[1.1.1]pent-1-yl or phenyl; and wherein phenyl is unsubstituted or substituted by 1, 2, 3 or up to the maximum possible number of identical or different radicals selected from fluorine, chlorine, cyano, OH, NH2, methyl, ethyl, methoxy, trifluoromethyl, trifluoromethoxy, difluoromethyl, difluoromethoxy and cyclopropyl; and
[0165] R 2 is hydrogen, methyl or ethyl.
[0166] In another preferred embodiment, the variable R in the compounds of formula I, Ib, II.b, IV, V and VI 1 and R 2 Has the following meanings:
[0167] R 1 is methyl, 2-methoxyiminoethyl, bicyclo[1.1.1]pent-1-yl, 2-fluorophenyl, 4-fluorophenyl or 2,4-difluorophenyl; in particular methyl or 2-fluorophenyl;
[0168] R 2 It's hydrogen.
[0169] The amide oxime compounds of formula II or II.b can be prepared from the cyano compounds of formula V by treating with hydroxylamine or its hydrochloride in the presence of a base, preferably triethylamine, sodium hydroxide or sodium methoxide, in a suitable solvent such as methanol, ethanol or water or a mixture of these solvents at a temperature of 0°C to 100°C.
[0170] NΞC-AR V
[0171] wherein variables A and R are as defined or preferably defined herein for compounds of formula I or Ib. For relevant examples, see Kitamura, S. et al., Chem. Pharm. Bull. 2001, 49, 268 or any of the patent references cited above. Compounds of formula V are commercially available or can be prepared from readily available starting materials using standard procedures known to those skilled in the art.
[0172] In a particularly advantageous two-step process (reaction scheme below), the variable R 1 and R 2 A cyano compound of the formula Va as defined or preferably defined herein is reacted with hydroxylamine or its hydrochloride or its hydrogen sulfate in an alcoholic solvent of the formula III as defined or preferably defined herein and optionally in the presence of a base to obtain a compound of the formula II.b, which can subsequently be reacted according to the process of the invention with a trifluoroacetate of the formula II.a in the presence of a base IV to prepare a compound of the formula Ib.
[0173] This two-step sequence can be carried out using the same solvent of formula V in two consecutive steps and does not require changing the reaction vessel between steps, thus eliminating the need to isolate and work up compound II.b. 1 is hydrogen and R 2 This two-step conversion is particularly preferred for compounds Va, II.b and Ib which are 2-fluorophenyl; and wherein the solvent III is methanol, ethanol, isopropanol, n-butanol or 2-butanol; in particular methanol or ethanol; and wherein the base IV in the second step is sodium ethoxide or sodium methoxide.
[0174]
[0175] The term "auxiliary solvent" herein refers to an inert solvent, i.e. a solvent that does not participate in the reaction and is not an alkyl alcohol under the definition of the compound of formula III. This means that the auxiliary solvent is different from the reactants (amide oxime II and haloacetic acid ester of formula II.a).
[0176] The term "conjugated Brønsted base" refers to the common definition, which is a member of a pair of compounds that interconvert by gain or loss of a proton, with the conjugate base being the species that has released the proton.
[0177] In the definitions of the variables given above, collective terms are used which generally represent the substituents involved.
[0178] The term "C n -C m ” indicates in each case the possible number of carbon atoms in the substituent or substituent moiety in question.
[0179] The term "halogen" refers to fluorine, chlorine, bromine and iodine.
[0180] The term "oxo" refers to an oxygen atom =0, which is bonded to a carbon atom or a sulfur atom, thereby forming, for example, a keto group -C(=O)- or a sulfinyl group -S(=O)-.
[0181] The term "C1-C6-alkyl" refers to a straight-chain or branched saturated hydrocarbon radical having 1 to 6 carbon atoms, for example methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl and 1,1-dimethylethyl.
[0182] The term "C2-C6-alkenyl" refers to a straight-chain or branched unsaturated hydrocarbon group having 2 to 6 carbon atoms and a double bond at any position, such as ethenyl, 1-propenyl, 2-propenyl (allyl), 1-methylethenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-methyl-1-propenyl, 2-methyl-1-propenyl, 1-methyl-2-propenyl, 2-methyl-2-propenyl.
[0183] The term "C2-C6-alkynyl" refers to a straight-chain or branched unsaturated hydrocarbon group having 2 to 6 carbon atoms and containing at least one triple bond, such as ethynyl, 1-propynyl, 2-propynyl (propargyl), 1-butynyl, 2-butynyl, 3-butynyl, 1-methyl-2-propynyl.
[0184] The term "C1-C6-haloalkyl" refers to straight-chain or branched alkyl groups (as defined above) having 1 to 6 carbon atoms, wherein some or all of the hydrogen atoms in these groups may be replaced by halogen atoms as mentioned above, for example chloromethyl, bromomethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chlorofluoromethyl, dichlorofluoromethyl, chlorodifluoromethyl, 1-chloroethyl, 1-bromoethyl, 1-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-chloro-2-fluoroethyl, 2-chloro-2,2-difluoroethyl, 2,2-dichloro-2 -fluoroethyl, 2,2,2-trichloroethyl and pentafluoroethyl, 2-fluoropropyl, 3-fluoropropyl, 2,2-difluoropropyl, 2,3-difluoropropyl, 2-chloropropyl, 3-chloropropyl, 2,3-dichloropropyl, 2-bromopropyl, 3-bromopropyl, 3,3,3-trifluoropropyl, 3,3,3-trichloropropyl, CH2-C2F5, CF2-C2F5, CF(CF3)2, 1-(fluoromethyl)-2-fluoroethyl, 1-(chloromethyl)-2-chloroethyl, 1-(bromomethyl)-2-bromoethyl, 4-fluorobutyl, 4-chlorobutyl, 4-bromobutyl or nonafluorobutyl.
[0185] The term "C1-C6-alkoxy" refers to a straight-chain or branched alkyl group having 1 to 6 carbon atoms (as defined above) bonded via an oxygen in any position of the alkyl group, for example methoxy, ethoxy, n-propoxy, 1-methylethoxy, butoxy, 1-methylpropoxy, 2-methylpropoxy or 1,1-dimethylethoxy.
[0186] The term "C1-C6-haloalkoxy" refers to a C1-C6-alkoxy group as defined above in which some or all of the hydrogen atoms may be replaced by halogen atoms as mentioned above, for example OCH2F, OCHF2, OCF3, OCH2Cl, OCHCl2, OCCl3, chlorofluoromethoxy, dichlorofluoromethoxy, chlorodifluoromethoxy, 2-fluoroethoxy, 2-chloroethoxy, 2-bromoethoxy, 2-iodoethoxy, 2,2-difluoroethoxy, 2,2,2-trifluoroethoxy, 2-chloro-2-fluoroethoxy, 2-chloro-2,2-difluoroethoxy, 2,2-dichloro-2- ... , 2-trichloroethoxy, OC2F5, 2-fluoropropoxy, 3-fluoropropoxy, 2,2-difluoropropoxy, 2,3-difluoropropoxy, 2-chloropropoxy, 3-chloropropoxy, 2,3-dichloropropoxy, 2-bromopropoxy, 3-bromopropoxy, 3,3,3-trifluoropropoxy, 3,3,3-trichloropropoxy, OCH2-C2F5, OCF2-C2F5, 1-(CH2F)-2-fluoroethoxy, 1-(CH2Cl)-2-chloroethoxy, 1-(CH2Br)-2-bromoethoxy, 4-fluorobutoxy, 4-chlorobutoxy, 4-bromobutoxy or nonafluorobutoxy.
[0187] The term "phenyl-C1-C4-alkyl or heteroaryl-C1-C4-alkyl" refers to an alkyl group having 1 to 4 carbon atoms (as defined above) wherein one of the hydrogen atoms of the alkyl group is replaced by a phenyl or heteroaryl group, respectively.
[0188] The term "C1-C4-alkoxy-C1-C4-alkyl" refers to an alkyl group (as defined above) having 1 to 4 carbon atoms in which one of the hydrogen atoms of the alkyl group is replaced by a C1-C4-alkoxy group (as defined above). Similarly, the term "C1-C4-alkylthio-C1-C4-alkyl" refers to an alkyl group (as defined above) having 1 to 4 carbon atoms in which one of the hydrogen atoms of the alkyl group is replaced by a C1-C4-alkylthio group.
[0189] The term "C1-C6-alkylthio" as used herein refers to a straight-chain or branched alkyl group (as defined above) having 1 to 6 carbon atoms bonded via a sulfur atom. Accordingly, the term "C1-C6-haloalkylthio" as used herein refers to a straight-chain or branched haloalkyl group (as defined above) having 1 to 6 carbon atoms bonded via a sulfur atom at any position in the haloalkyl group.
[0190] The term "C1-C4-alkoxyimino" refers to a divalent imino group (C1-C4-alkyl-ON=) having a C1-C4-alkoxy group as a substituent, for example, methylimino, ethylimino, propylimino, 1-methylethylimino, butylimino, 1-methylpropylimino, 2-methylpropylimino, 1,1-dimethylethylimino, and the like.
[0191] The term "C1-C6-alkoxyimino-C1-C4-alkyl" refers to an alkyl group having 1 to 4 carbon atoms in which two hydrogen atoms of one carbon atom of the alkyl group are replaced by a divalent C1-C6-alkoxyimino group (C1-C6-alkyl-ON=) as defined above.
[0192] The term "C2-C6-alkenyloxyimino-C1-C4-alkyl" refers to an alkyl group having 1 to 4 carbon atoms in which two hydrogen atoms of one carbon atom of the alkyl group are replaced by a divalent C2-C6-alkenyloxyimino group (C2-C6-alkenyl-ON=).
[0193] The term "C2-C6-alkynyloxyimino-C1-C4-alkyl" refers to an alkyl group having 1 to 4 carbon atoms in which two hydrogen atoms of one carbon atom of the alkyl group are replaced by a divalent C2-C6-alkynyloxyimino group (C2-C6-alkynyl-ON=).
[0194] The term "hydroxy C1-C4-alkyl" refers to an alkyl group having 1 to 4 carbon atoms in which one of the hydrogen atoms of the alkyl group is replaced by an OH group.
[0195] The term "amino C1-C4-alkyl" refers to an alkyl group having 1 to 4 carbon atoms wherein one of the hydrogen atoms of the alkyl group is replaced by an NH2 group.
[0196] The term "C1-C6-alkylamino" refers to an amino group substituted by one residue independently selected from the group defined by the term C1-C6-alkyl. Similarly, the term "di-C1-C6-alkylamino" refers to an amino group substituted by two residues independently selected from the group defined by the term C1-C6-alkyl.
[0197] The term "C1-C4-alkylamino-C1-C4-alkyl" refers to an alkyl group having 1 to 4 carbon atoms (as defined above) in which one of the hydrogen atoms of the alkyl group is replaced by a C1-C4-alkyl-NH-group bonded via nitrogen. Similarly, the term "di-C1-C4-alkylamino-C1-C4-alkyl" refers to an alkyl group having 1 to 4 carbon atoms (as defined above) in which one of the hydrogen atoms of the alkyl group is replaced by a (C1-C4-alkyl)2N-group bonded via nitrogen.
[0198] The term "aminocarbonyl-C1-C4-alkyl" refers to an alkyl group having 1 to 4 carbon atoms wherein one of the hydrogen atoms of the alkyl group is replaced by a -(C=O)-NH2 group.
[0199] The term "C3-C 11 "-Cycloalkyl" refers to a monocyclic, bicyclic or tricyclic saturated monovalent hydrocarbon radical having 3 to 11 carbon ring members attached via one of the ring carbon atoms by replacing one hydrogen atom, such as cyclopropyl (C3H5), cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[1.1.0]butyl, bicyclo[2.1.0]pentyl, bicyclo[1.1.1]pentyl, bicyclo[3.1.0]hexyl, bicyclo[2.1.1]hexyl, norcarbyl (bicyclo[4.1.0]heptyl) and norbornyl (bicyclo[2.2.1]heptyl).
[0200] The terms "-C(=O)-C1-C6-alkyl", "-C(=O)-O-C1-C6-alkyl" and "-C(=O)-C3-C 11 "-Cycloalkyl" refers to an aliphatic group attached via a carbon atom of a -C(=O)- group.
[0201] The term "aliphatic" refers to compounds or groups that are composed of carbon and hydrogen and are non-aromatic compounds. "Alicyclic" compounds or groups are organic compounds that are both aliphatic and cyclic. They contain one or more all-carbon rings that may be saturated or unsaturated but do not have aromatic character.
[0202] The term "cyclic moiety" or "cyclic group" refers to a group that is an alicyclic ring or an aromatic ring, such as a phenyl group or a heteroaryl group.
[0203] The term "and wherein any aliphatic or cyclic group is unsubstituted or substituted by..." refers to aliphatic groups, cyclic groups and groups containing aliphatic and cyclic moieties in one group, such as in, for example, C3-C8-cycloalkyl-C1-C4-alkyl; thus, groups containing aliphatic and cyclic moieties - these moieties can be substituted or unsubstituted independently of each other.
[0204] The term "phenyl" refers to an aromatic ring system (commonly referred to as a benzene ring) comprising 6 carbon atoms.
[0205] The term "heteroaryl" refers to an aromatic monocyclic or multicyclic ring system which includes 1, 2, 3 or 4 heteroatoms independently selected from N, O and S in addition to carbon atoms.
[0206] The term "saturated 3- to 7-membered carbocycle" is understood to mean a monocyclic saturated carbocycle having 3, 4 or 5 carbon ring members. Examples include cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl and the like.
[0207] The term "3- to 10-membered saturated, partially unsaturated or aromatic monocyclic or bicyclic heterocycle, wherein the ring member atoms of the monocyclic or bicyclic heterocycle include, besides carbon atoms, further 1, 2, 3 or 4 heteroatoms selected from N, O and S as ring member atoms" is understood to mean aromatic monocyclic and bicyclic heteroaromatic ring systems, and saturated and partially unsaturated heterocycles, for example:
[0208] 3- or 4-membered saturated heterocycles containing 1 or 2 heteroatoms selected from N, O and S as ring members, such as oxirane, aziridine, thiirane, oxetane, azetidine, thiethane, [1,2]dioxetane, [1,2]dithietane, [1,2]diazetidine;
[0209] and a 5- or 6-membered saturated or partially unsaturated heterocyclic ring containing 1, 2 or 3 heteroatoms selected from N, O and S as ring members, such as 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydrothienyl, 3-tetrahydrothienyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 3-isothiophene, Oxazolidinyl, 4-iso Oxazolidinyl, 5-iso oxazolidinyl, 3-isothiazolidinyl, 4-isothiazolidinyl, 5-isothiazolidinyl, 3-pyrazolidinyl, 4-pyrazolidinyl, 5-pyrazolidinyl, 2- Oxazolidinyl, 4- Oxazolidinyl, 5- oxazolidinyl, 2-thiazolidinyl, 4-thiazolidinyl, 5-thiazolidinyl, 2-imidazolidinyl, 4-imidazolidinyl, 1,2,4- oxadiazolidine-3-yl, 1,2,4- 1,2,4-thiadiazolidin-5-yl, 1,2,4-thiadiazolidin-3-yl, 1,2,4-thiadiazolidin-5-yl, 1,2,4-triazolidin-3-yl, 1,3,4- oxadiazolidin-2-yl, 1,3,4-thiadiazolidin-2-yl, 1,3,4-triazolidin-2-yl, 2,3-dihydrofuran-2-yl, 2,3-dihydrofuran-3-yl, 2,4-dihydrofuran-2-yl, 2,4-dihydrofuran-3-yl, 2,3-dihydrothiophen-2-yl, 2,3-dihydrothiophen-3-yl, 2,4-dihydrothiophen-2-yl, 2,4-dihydrothiophen-3-yl, 2-pyrrolidine-2-yl, 2-pyrrolidine-3-yl, 3-pyrrolidine-2-yl, 3-pyrrolidine-3-yl, 2-isothiophene-2-yl, 2-isothiophene ...3-yl, 2-isothiophene-2-yl, 2-isothiophene-3-yl, 2-isothiophene-3-yl, 2-isothiophene-3-yl, 2-isothiophene-2-yl, 2- Oxazoline-3-yl, 3-iso Oxazoline-3-yl, 4-iso Oxazoline-3-yl, 2-iso Oxazoline-4-yl, 3-iso Oxazolin-4-yl, 4-iso Oxazoline-4-yl, 2-iso Oxazoline-5-yl, 3-iso Oxazoline-5-yl, 4-iso oxazolin-5-yl, 2-isothiazolin-3-yl, 3-isothiazolin-3-yl, 4-isothiazolin-3-yl, 2-isothiazolin-4-yl, 3-isothiazolin-4-yl, 4-isothiazolin-4-yl, 2-isothiazolin-5-yl, 3-isothiazolin-5-yl, 4-isothiazolin-5-yl, 2,3-dihydropyrazol-1-yl, 2,3-dihydropyrazol-2-yl, 2,3-dihydropyrazol- -3-yl, 2,3-dihydropyrazol-4-yl, 2,3-dihydropyrazol-5-yl, 3,4-dihydropyrazol-1-yl, 3,4-dihydropyrazol-3-yl, 3,4-dihydropyrazol-4-yl, 3,4-dihydropyrazol-5-yl, 4,5-dihydropyrazol-1-yl, 4,5-dihydropyrazol-3-yl, 4,5-dihydropyrazol-4-yl, 4,5-dihydropyrazol-5 ...2,3-dihydropyrazol-5-yl, 2,3-dihydropyrazol-5-yl, 2,3-dihydropyrazol-3-yl, 3,4-dihydropyrazol-4-yl, 3,4-dihydropyrazol-5-yl, 4,5-dihydropyrazol-1-yl, 4,5-dihydropyrazol-3-yl, 4,5-dihydropyrazol-4-yl, 4,5-dihydropyrazol-5-yl, 2,3-dihydropyrazol-5-yl, 2,3-dihydropyrazol-5-yl, 2,3-dihydropyrazol- Oxazol-2-yl, 2,3-dihydro Oxazol-3-yl, 2,3-dihydro Oxazol-4-yl, 2,3-dihydro Oxazol-5-yl, 3,4-dihydro Oxazol-2-yl, 3,4-dihydro Oxazol-3-yl, 3,4-dihydro Oxazol-4-yl, 3,4-dihydro Oxazol-5-yl, 3,4-dihydro Oxazol-2-yl, 3,4-dihydro Oxazol-3-yl, 3,4-dihydro oxazol-4-yl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 1,3-dioxan-5-yl, 2-tetrahydropyranyl, 4-tetrahydropyranyl, 2-tetrahydrothienyl, 3-hexahydropyridazinyl, 4-hexahydropyridazinyl, 2-hexahydropyrimidinyl, 4-hexahydropyrimidinyl, 5-hexahydropyrimidinyl, 2-piperazinyl, 1,3,5-hexahydrotriazin-2-yl and 1,2,4-hexahydrotriazin-3-yl and the corresponding -subunits; and 7-membered saturated or partially unsaturated heterocycles, such as tetrahydro- and hexahydroazepines 2,3,4,5-tetrahydro[1H]azepine -1-, -2-, -3-, -4-, -5-, -6- or -7-yl, 3,4,5,6-tetrahydro[2H]azepine -2-, -3-, -4-, -5-, -6- or -7-yl, 2,3,4,7-tetrahydro[1H]azepine -1-, -2-, -3-, -4-, -5-, -6- or -7-yl, 2,3,6,7-tetrahydro[1H]azepine -1-, -2-, -3-, -4-, -5-, -6- or -7-yl, hexahydroazepine -1-, -2-, -3- or -4-yl, tetrahydro- and hexahydrooxepinyl, such as 2,3,4,5-tetrahydro[1H]oxepin-2-, -3-, -4-, -5-, -6- or -7-yl, 2,3,4,7-tetrahydro[1H]oxepin-2-, -3-, -4-, -5-, -6- or -7-yl, 2,3,6,7-tetrahydro[1H]oxepin-2-, -3-, -4-, -5-, -6- or -7-yl, hexahydroazepine -1-, -2-, -3- or -4-yl, tetrahydro- and hexahydro-1,3-diazepines 1,4-diazepine, tetrahydro- and hexahydro-1,4-diazepine 1,3-oxazepine Oxazepinyl, tetrahydro- and hexahydro-1,4-oxazepinyl 1,4-dioxepinyl, tetrahydro- and hexahydro-1,3-dioxepinyl, tetrahydro- and hexahydro-1,4-dioxepinyl and the corresponding -ylidenes.
[0210] The term "5- or 6-membered heteroaryl" or the term "5- or 6-membered aromatic heterocycle" refers to an aromatic ring system which, in addition to carbon atoms, comprises 1, 2, 3 or 4 heteroatoms independently selected from N, O and S, for example a 5-membered heteroaryl such as pyrrol-1-yl, pyrrol-2-yl, pyrrol-3-yl, thiophen-2-yl, thiophen-3-yl, furan-2-yl, furan-3-yl, pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, imidazol-1-yl, imidazol-2-yl, imidazol-4-yl, imidazol-5-yl, Oxazol-2-yl, Oxazol-4-yl, oxazol-5-yl, isoxazol-5-yl Oxazol-3-yl, iso Oxazol-4-yl, iso oxazol-5-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, 1,2,4-triazol-1-yl, 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl, 1,2,4- oxadiazole-3-yl, 1,2,4- oxadiazole-5-yl and 1,2,4-thiadiazol-3-yl, 1,2,4-thiadiazol-5-yl; or
[0211] 6-membered heteroaryl, such as pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyridazin-3-yl, pyridazin-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrazin-2-yl and 1,3,5-triazin-2-yl and 1,2,4-triazin-3-yl. Example
[0212] The present invention is further illustrated by means of the following examples.
[0213] Analytical method 1: HPLC Agilent 1100 Series; column: Agilent Zorbax Phenyl-Hexyl 1,8μm 50*4,6mm, column flow: 1mL / min, time: 25min, pressure: 20000kPa; temperature: 20°C; wavelength 200nm; injection volume: 2uL; retention time of each product is based on reference material.
[0214] Eluent: A: water containing 0.1 volume % H3PO4; B: acetonitrile
[0215] Time (min) %B Rate (mL / min) 0,0 14 1,0 16,0 86 1,0 20,0 86 1,0 20,1 14 1,0
[0216] Analytical method 2: HPLC Agilent 1100 Series; column: Agilent Zorbax Eclipse XDB-C181, 8μm 50*4,6mm von Agilent, column flow: 1,3mL / min, time: 10min, pressure: 23000kPa; temperature: 20°C; wavelength 195nm; injection volume: 1uL; the retention times of the respective products are based on reference materials and are given below.
[0217] Eluent: A: water containing 0.1 volume % H3PO4; B: acetonitrile
[0218] Time (min) %B Rate (mL / min) 0,0 0 1,3 2,0 0 1,3 5,0 80 1,3 6,0 100 1,3 8,0 100 1,3 8,1 0 1,3
[0219] Example 1) 3-(p-tolyl)-5-(trifluoromethyl)-1,2,4- Preparation of oxadiazole
[0220]
[0221] At 22°C, a container was loaded with 40.0 g (256 mmol, 96.0% purity) of N'-hydroxy-4-methyl-benzamidine and 181 g (1.28 mol) of ethyl trifluoroacetate. 27.6 g of sodium methoxide (151 mmol, 30% w / w in methanol) was added over 30 minutes and the reaction mixture was stirred at 30°C for 1.5 hours. Then, another 13.8 g of sodium methoxide (75.5 mmol, 30% w / w in methanol) was added over 10 minutes and the mixture was stirred for another 40 minutes. A final 13.8 g of sodium methoxide (75.5 mmol, 30% w / w in methanol) was added over 10 minutes and the mixture was stirred for another 30 minutes. 2.3 g of hydrochloric acid (32% w / w) was added and all volatiles were removed under reduced pressure. Water (60 g) was added and the phases were separated. From the organic phase, 57.4 g (94.8%, HPLC purity (method 1): 96.3%) of the title compound were isolated.
[0222] Example 2) N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4- Preparation of oxadiazole-3-yl]benzamide
[0223]
[0224] Example 2.1) TFAE as reagent:
[0225] 500 mg (1.83 mmol) of N-(2-fluorophenyl)-4-[(Z)-N'-hydroxyamidino]benzamide and 5 ml of N,N-dimethylformamide were loaded into a flask at room temperature. 416 mg (2.93 mmol) of ethyl trifluoroacetate were added to this reaction mass at room temperature, followed by dropwise addition of 527 mg of sodium methoxide (2.93 mmol, 30% w / w in methanol). A slight exotherm was observed during this addition and the reaction mass became reddish brown. The reaction mass was stirred at room temperature for another 1 hour. HPLC analysis confirmed complete conversion. Water was then added to the reaction mass, which precipitated the product. The product was filtered, the filter cake was washed with water to remove N,N-dimethylformamide, and then dried to produce 0.53 g (84.6%, HPLC purity (method 1): 97.2%) of the title compound.
[0226] Example 2.2) TFAE as solvent:
[0227] A vessel was charged with 18.9 g (67.4 mmol, 97.5% purity) of N-(2-fluorophenyl)-4-[(Z)-N'-hydroxyamidino]benzamide and 200 g (1.39 mol, 99% purity) of ethyl trifluoroacetate at 20°C. 13.4 g of sodium methoxide (74.4 mmol, 30% w / w in methanol) were added over 3 minutes and the reaction was stirred for 16 hours. All volatiles were then removed under reduced pressure, methanol (100 ml) and water (20 ml) were added and the solids were collected by filtration. The filter cake was washed with water (2 x 20 ml) and dried.
[0228] Isolated dry weight of title product: 20.4 g (83.4%), HPLC purity (method 1): 96.8%.
[0229] Example 2.3) TFAE as solvent:
[0230] 18.9 g (67.6 mmol, purity 97.8%) N-(2-fluorophenyl)-4-[(Z)-N'-hydroxyamidino]benzamide and 200 g (1.39 mol, purity 99%) ethyl trifluoroacetate were loaded into a vessel at 20°C. 18.3 g sodium methoxide (100 mmol, 30% w / w in methanol) were added over 5 minutes and the reaction mixture was stirred for 3 hours, after which another portion of sodium methoxide (6.1 g, 33.3 mmol) was added. Isopropanol (200 ml) was added, the mixture was heated to 70°C and a portion of the volatiles was removed. The resulting mixture was cooled to ambient temperature and stirred for 16 hours, then water (200 ml) was added, which precipitated the product. The title product was collected by filtration. The filter cake was washed with water (2×50 ml) and dried. Dry weight of the isolated title product: 20.4 g (93.4%), HPLC purity (method 1): 98.1%.
[0231] Example 2.4) TFAE as reagent:
[0232] N-(2-fluorophenyl)-4-[(Z)-N'-hydroxyamidino]benzamide (5 g, 1 eq), ethanol (60 ml) and ethyl trifluoroacetate (6.5 g, 2.5 eq) were loaded into a flask under a nitrogen atmosphere at ambient temperature. Sodium ethoxide (21% w / w in ethanol, 8.3 ml, 1.4 eq) was added to this reaction mass at ambient temperature over 13 minutes, and the reaction mixture was then stirred at ambient temperature for 60 minutes. After the reaction was complete, water (100 ml) was added and the resulting mixture was stirred at ambient temperature for 30 minutes, which precipitated the product. The title product was collected by filtration. The filter cake was washed with water (50 ml) and dried under vacuum, which produced the title product as a colorless solid at 98% (HPLC purity (method 1): 99.9%).
[0233] Example 2.5) TFAE as reagent:
[0234] N-(2-fluorophenyl)-4-[(Z)-N'-hydroxyamidino]benzamide (5 g, 1 eq) and toluene (100 ml) were loaded into a flask at ambient temperature under a nitrogen atmosphere, followed by the addition of sodium ethoxide (21% in ethanol, 11.9 ml, 2.0 eq). Ethyl trifluoroacetate (5.2 g, 2.0 eq) was added and the resulting mixture was stirred at ambient temperature for 3 hours. After the reaction was complete, toluene was removed under reduced pressure, water (100 ml) was added and the resulting mixture was stirred at ambient temperature for 30 minutes. The solid was collected by filtration and washed with water (50 ml). Drying under vacuum produced the title product as a colorless solid at 96.9% (HPLC purity (method 1): 99.4%).
[0235] Example 2.6) TFAE as reagent:
[0236] N-(2-fluorophenyl)-4-[(Z)-N'-hydroxyamidino]benzamide (27.5 g, 1 eq) and ethanol (224 g) were loaded into a flask under a nitrogen atmosphere. Sodium ethoxide (21% w / w in ethanol, 41 g, 1.30 eq) was added over 10 min at ambient temperature and the resulting mixture was heated to 51 °C. After 15 min at 51 °C, ethyl trifluoroacetate (99%, 35 g, 2.5 eq) was added over 35 min and the reaction temperature was maintained at 51 °C for 5 hours. Water (400 g) was then added over 2 hours. The mixture was slowly cooled to ambient temperature and then further cooled to 10 °C. The solid was collected by filtration and washed with water (2 x 100 ml). Drying under vacuum produced the desired product as a colorless solid at 96.5% (HPLC purity (method 1): 98.6%).
[0237] Example 2.7) TFAE as reagent:
[0238] A flask was loaded with N-(2-fluorophenyl)-4-[(Z)-N'-hydroxyamidino]benzamide (33.2 g, 98.8% purity, 1 eq.). A mixture of methanol (76.8 g) and ethyl trifluoroacetate (37.5 g, 100% purity, 2.2 eq.) was added under a nitrogen atmosphere. The reaction mixture was cooled to below 20°C and sodium methoxide (30% w / w in methanol, 25.9 g, 1.20 eq.) was added over 8 minutes at a temperature below 25°C. The resulting mixture was stirred at 25°C for 5 hours. Demineralized water (48 g) was then added at 25°C with stirring. The suspended solid was collected by filtration. Drying under vacuum produced the desired product as a colorless solid at 96.2% (HPLC purity (Method 1): 93.4%).
[0239] Example 3) 3-[4-(trichloromethyl)phenyl]-5-(trifluoromethyl)-1,2,4- Preparation of oxadiazole
[0240] 300 g (1.31 mol) of 3-(p-tolyl)-5-(trifluoromethyl)-1,2,4- The oxadiazole was placed in a 500 ml quartz glass round bottom flask. 427 g of chlorine (6.0 mol) was passed into the reactor, heated to 125°C, and irradiated with a Heraeus TQ150 Watt (mercury medium pressure emitter) UV lamp for 8 hours. After the reaction was completed, the reaction mass was stripped with nitrogen to remove the remaining chlorine and hydrogen chloride gases. GC analysis showed 98.7ar% product. Yield: 437 g crystalline product; 99%; Melting point: 75°C-78°C; 1 H-NMR (CDCl3): 8.1ppm (m, 2H, 2×CH); 8.3ppm (m, 2H, 2×CH).
[0241] Example 4) N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4- Preparation of oxadiazole-3-yl]benzamide
[0242] 150 g (0.446 mol) of solid 3-[4-(trichloromethyl)phenyl]-5-(trifluoromethyl)-1,2,4- Oxadiazole and 3.75 g (0.023 mol) of iron (III) chloride were placed in a 0.75 liter reactor equipped with an overhead stirrer, a reflux condenser and an exhaust scrubber. The reactor was heated to 120° C. and 7.6 g (0.422 mol) of water were metered into the reaction mixture over 3 hours and stirred for another 30 minutes. The reaction mixture was then cooled to 25° C. and 300 g (4.156 mol) of tetrahydrofuran were added, and the reaction mixture was cooled to 10° C. A solution of 56 g of 2-fluoroaniline (0.489 mol), 50 g of triethylamine (0.489 mol) and 200 g of tetrahydrofuran (2.771 mol) was then added over approximately 40 minutes, while the temperature of the reaction mixture was maintained between 10° C. and 25° C. and the line was flushed with 100 g (1.4 mol) of tetrahydrofuran. After stirring overnight, the mixture was cooled to 5° C. and 450 ml of water were added. The solid was filtered off and washed twice with 100 g of cold water. A solid material was obtained which was dried (80° C., 2 kPa) to yield 130 g (0.363 mol) of the title product. HPLC analysis (Method 2) showed >98 ar% product.
[0243] Example 5) N-methyl-4-[5-(trifluoromethyl)-1,2,4- Preparation of oxadiazole-3-yl]benzamide
[0244] 5 g (0.015 mol) of solid 3-[4-(trichloromethyl)phenyl]-5-(trifluoromethyl)-1,2,4- The oxadiazole and 0.12 g (0.74 mmol) of iron (III) chloride were placed in a 0.75 liter reactor equipped with an overhead stirrer, a reflux condenser and an exhaust gas scrubber. The reactor was heated to 85° C. and 0.26 g (0.014 mol) of water was metered into the reaction mixture over 1 hour and stirred for a further 40 minutes. The temperature was then cooled to 25° C. and 14.6 g (0.222 mol) of tetrahydrofuran was added and the reaction mixture was cooled to 0° C. 27 ml (5 M, 0.074 mmol) of methylamine / tetrahydrofuran solution were then added and stirred overnight at room temperature. Water and ethyl acetate were added and the phases separated. The organic phase was washed with water and dried over magnesium sulfate / activated carbon. Filtration and removal of volatiles yielded 2.9 g (HPLC analysis (method 2): 88 ar%, 0.091 mol, retention time = 0.93 min, M+ = 271) of N-methyl-4-[5-(trifluoromethyl)-1,2,4- oxadiazol-3-yl]benzamide.
[0245] Example 6) N-methyl-4-[5-(trifluoromethyl)-1,2,4- Preparation of oxadiazole-3-yl]thiobenzamide
[0246] 15 g (54.8 mmol) of N-methyl-4-[5-(trifluoromethyl)-1,2,4- [3-oxadiazole] benzamide and 3.8 g (16.9 mmol) of phosphorus (V) sulfide were dissolved in 87 g of toluene and heated to 112° C. for 1 hour. The reaction mixture was treated with 100 g of water and 100 g of toluene at below 100° C. After phase separation at 75° C., the organic phase was separated and washed with 100 g of water. The volatiles were removed in vacuo (80° C., 200 to 5 mbar) to give 15.8 g of crude product, which was suspended in 50 ml of diisopropyl ether and heated to 60° C. for 1 hour. After cooling to room temperature, the precipitate was filtered off and washed with 20 ml of diisopropyl ether. After drying at 80° C. and under reduced pressure, 13.5 g (44.2 mmol, HPLC analysis (method 2): 94 ar%) of N-methyl-4-[5-(trifluoromethyl)-1,2,4- oxadiazol-3-yl]thiobenzamide. 1 H-NMR (δ / ppm, CDCl3, 400MHz): 3.4ppm, s, 3H; 7.8, s, br 1H; 7.9, d, 2H; 8.1, d, 2H).
Claims
1. A method for preparing a compound of formula I Methods for producing oxadiazole compounds, in A is phenyl or a 5- or 6-membered aromatic heterocycle; wherein the ring member atoms of the aromatic heterocycle include, in addition to carbon atoms, 1, 2, 3 or 4 heteroatoms selected from N, O and S as ring member atoms, provided that the heterocycle cannot contain 2 adjacent atoms selected from O and S; and wherein A is further unsubstituted or further substituted by n additional identical or different groups R A Replace; n is 0, 1, 2, 3 or 4; R A independently selected from halogen, cyano, C1-C6-alkyl, C1-C6-haloalkyl, C1-C6-alkoxy and C1-C6-haloalkoxy; R is methyl, chloromethyl, hydroxymethyl, trichloromethyl, ethyl, isopropyl, OH, SH, cyano, halogen, CH2F, CHF2, 2,2,2-trifluoroethyl, cyclopropyl, -C(=NOR 2 )H, -C(=O)OH, -C(=O)OR 1 、-C(=W)NR 1 R 2 , -CR 3 R 4 NR 1 R 2 , -CR 3 R 4 OR 1 , -CR 3 (=NR 1 ),-CR 3 (=O)、-CR 3 R 4 C(=O)OH、-CR 3 R 4 C(=O)R 1 , -CR 3 R 4 C(=W)NR 1 R 2 , -OCR 3 R 4 C(=O)OH、-OCR 3 R 4 C(=O)R 1 , -OCR 3 R 4 C(=W)NR 1 R 2 , -CR 3 R 4 -N(R2 )-C(=W)R 1 , -CR 3 R 4 S(=O)2R 1 or -CR 3 R 4 -N(R 2 )-S(=O)2R 1 ;in W is O or S; R 2 is hydrogen, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-alkoxy, C3-C 11 -cycloalkyl, -C(=O)-C1-C6-alkyl, -C(=O)-C3-C 11 -cycloalkyl or -C(=O)-O-C1-C6-alkyl; and wherein R 2 Any aliphatic or cyclic group in is unsubstituted or replaced by 1, 2 or 3 groups selected from halogen, hydroxy, oxo, cyano, C1-C6-alkyl, C1-C6-alkoxy and C3-C 11 - substitution of cycloalkyl groups by the same or different groups; R 1 It is C1-C6-alkyl, C1-C6-alkoxy, C3-C 11 -cycloalkyl, C3-C8-cycloalkenyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-alkoxyimino-C1-C4-alkyl, C2-C6-alkenyloxyimino-C1-C4-alkyl, C2-C6-alkynyloxyimino-C1-C4-alkyl, C1-C6-alkylamino, di-C1-C6-alkylamino, -C(=O)-C1-C6-alkyl, -C(=O)-O-C1-C6-alkyl, phenyl-C1-C4-alkyl, phenyl-C1-C4-alkenyl, phenyl-C1-C4-alkynyl, heteroaryl-C1-C4-alkyl, phenyl, naphthyl or a 3- to 10-membered saturated, partially unsaturated or aromatic wherein the ring member atoms of the monocyclic or bicyclic heterocyclic ring further include, in addition to carbon atoms, 1, 2, 3 or 4 heteroatoms selected from N, O and S as ring member atoms, provided that the heterocyclic ring cannot contain 2 adjacent atoms selected from O and S; and wherein the heteroaryl in the group heteroaryl-C1-C4-alkyl is a 5- or 6-membered aromatic heterocyclic ring, wherein the ring member atoms of the heterocyclic ring further include, in addition to carbon atoms, 1, 2, 3 or 4 heteroatoms selected from N, O and S as ring member atoms, provided that the heterocyclic ring cannot contain 2 adjacent atoms selected from O and S; and wherein any of the above aliphatic or cyclic groups is unsubstituted or replaced by 1, 2, 3 identical or different groups R 1a replace; or R 1 and R2 , together with the nitrogen atom to which they are attached, form a saturated or partially unsaturated monocyclic or bicyclic 3- to 10-membered heterocyclic ring, wherein the heterocyclic ring does not contain other heteroatoms besides one nitrogen atom and one or more carbon atoms or contains 1, 2 or 3 heteroatoms independently selected from N, O and S as ring member atoms besides one nitrogen atom and one or more carbon atoms, provided that the heterocyclic ring cannot contain 2 adjacent atoms selected from O and S; and wherein the heterocyclic ring is unsubstituted or replaced by 1, 2, 3 or 4 identical or different groups R 1a Replace; R 1a is halogen, oxo, cyano, NO2, OH, SH, NH2, C1-C6-alkyl, C1-C6-haloalkyl, C1-C6-alkoxy, C1-C6-haloalkoxy, C1-C6-alkylthio, C1-C6-haloalkylthio, C3-C8-cycloalkyl, -NHSO2-C1-C4-alkyl, -C(=O)-C1-C4-alkyl, -C(=O)-O-C1-C4-alkyl, C1-C6-alkyl C1-C4-alkyl, -C(═O)-NH2, -C(═O)-NH(C1-C4-alkyl), C1-C4-alkylthio-C1-C4-alkyl, aminoC1-C4-alkyl, C1-C4-alkylamino-C1-C4-alkyl, di-C1-C4-alkylamino-C1-C4-alkyl, aminocarbonyl-C1-C4-alkyl or C1-C4-alkoxy-C1-C4-alkyl; R 3 , R 4 are independently selected from hydrogen, halogen, cyano, C1-C4-alkyl, C1-C4-alkenyl, C1-C4-alkynyl, C1-C4-haloalkyl and C1-C4-alkoxy; or R 3 and R 4 Together with the carbon atom to which they are bonded, they form a cyclopropyl group; The method comprises reacting an amide oxime of formula II with a haloacetic acid ester of formula II.a in the presence of a solvent and a base, wherein the variables A and R are as defined above for compounds of formula I, Where R 5 is C1-C6-alkyl; wherein the method is carried out at a temperature of 0°C to 60°C; The method is characterized in that the base is sodium methoxide or sodium ethoxide or a mixture thereof; and the solvent comprises methanol or ethanol or a mixture thereof; The amount of the haloacetic acid ester of the formula II.a is between 1 and 5 equivalents, based on the amount of the amide oxime II.
2. The process according to claim 1, wherein the solvent contains at least 1% by volume of methanol or ethanol or a mixture thereof, based on the total amount of solvent, and the other solvents comprise auxiliary solvents or a halogenated acetic acid ester of formula II.a or a mixture thereof.
3. The process according to claim 1, wherein the process is carried out at a temperature of 10°C to 50°C.
4. The process according to claim 2, wherein the process is carried out at a temperature of 10°C to 50°C.
5. A process according to any one of claims 1 to 4, wherein the radical R in the haloacetic acid ester of formula II.a 5 It is methyl or ethyl.
6. The process according to any one of claims 1 to 4, wherein the amide oxime compound is of the formula II.b, Where n is 0 or 1, and R A and R have the same meaning as defined in claim 1 for the compound of formula I, to obtain a compound of formula Ib Oxadiazole, The variables n, R A and R have the meanings as defined for compound II.b.
7. A method according to claim 6, wherein the variables have the following meanings: n is 0; R is -C(=O)NR 1 R 2 ; R 1 is methyl, 2-methoxyiminoethyl, bicyclo[1.1.1]pent-1-yl, 2-fluorophenyl, 4-fluorophenyl or 2,4-difluorophenyl; R 2 It's hydrogen.
8. The method according to claim 7, wherein R 1 is methyl or 2-fluorophenyl.
9. The method according to claim 7, further comprising making the variable R 1 and R 2 Step of reacting a compound of formula Va as defined for a compound of formula II.b to obtain a compound of formula II.b 10. The process according to claim 6, wherein in the compounds of formula Ib and II.b n is 0 and R is methyl, and further comprising the step of reacting the compound of formula Ib to obtain the compound of formula Ic 11. The process according to claim 6, wherein in the compounds of formula Ib and II.b n is 0 and R is -C(=O)OH, and further comprising the step of reacting the compound of formula Ib to obtain the compound of formula III.a 12. The method according to claim 10, further comprising the step of reacting the compound of formula Ic to obtain the compound of formula III.a 13. The method according to claim 11 or 12, further comprising the step of reacting a compound of formula III.a with a compound of formula IV to obtain a compound of formula V R 1 -NH-R 2 IV, Wherein R 1 and R 2 As defined in any of the preceding claims for a compound of formula I 14. The method according to claim 13, further comprising the step of reacting the compound of formula V to obtain the compound of formula VI 15. The method according to claim 14, wherein in the compounds of formula IV, V and VI R 1 is methyl, 2-methoxyiminoethyl, bicyclo[1.1.1]pent-1-yl, 2-fluorophenyl, 4-fluorophenyl or 2,4-difluorophenyl; R 2 It's hydrogen.
16. The method according to claim 15, wherein R 1 is methyl or 2-fluorophenyl.
